Krishnamurthy, A., Wang, H., Rhee, J. C., Davar, D., Moy, R. H., Ratner, L., Christner, S. M., Holleran, J. L., Deppas, J., Sclafani, C., Schmitz, J. C., Gore, S., Chu, E., Bakkenist, C. J., Beumer, J. H., & Villaruz, L. C. (2025). Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-024-04745-6

Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., Sharp, A., Sheehan, B., Christova, R., Seed, G., Figueiredo, I., Lambros, M., Dolling, D., Rekowski, J., Alajati, A., … de Bono, J. (2021). HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Research, 81(24), 6207–6218. https://doi.org/10.1158/0008-5472.can-21-3360